Tomasini, P.; Serdjebi, C.; Khobta, N.; Metellus, P.; Ouafik, L.; Nanni, I.; Greillier, L.; Loundou, A.; Fina, F.; Mascaux, C.;
et al. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2016, 17, 2132.
https://doi.org/10.3390/ijms17122132
AMA Style
Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, Greillier L, Loundou A, Fina F, Mascaux C,
et al. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2016; 17(12):2132.
https://doi.org/10.3390/ijms17122132
Chicago/Turabian Style
Tomasini, Pascale, Cindy Serdjebi, Nataliya Khobta, Philippe Metellus, L’Houcine Ouafik, Isabelle Nanni, Laurent Greillier, Anderson Loundou, Frederic Fina, Celine Mascaux,
and et al. 2016. "EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer" International Journal of Molecular Sciences 17, no. 12: 2132.
https://doi.org/10.3390/ijms17122132
APA Style
Tomasini, P., Serdjebi, C., Khobta, N., Metellus, P., Ouafik, L., Nanni, I., Greillier, L., Loundou, A., Fina, F., Mascaux, C., & Barlesi, F.
(2016). EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 17(12), 2132.
https://doi.org/10.3390/ijms17122132